[go: up one dir, main page]

Kohtz et al., 1988 - Google Patents

Immunological and structural homology between human T-cell leukemia virus type I envelope glycoprotein and a region of human interleukin-2 implicated in binding …

Kohtz et al., 1988

View PDF
Document ID
7093680590895636423
Author
Kohtz D
Altman A
Kohtz J
Puszkin S
Publication year
Publication venue
Journal of virology

External Links

Snippet

The N-terminal segment of human interleukin-2 (hIL-2) appears to mediate binding of the beta hIL-2 receptor (R. Robb, C. Rusk, J. Yodoi, and W. Greene, Proc. Natl. Acad. Sci. USA 84: 2002-2006, 1987). An affinity-purified antibody prepared against this peptide segment …
Continue reading at journals.asm.org (PDF) (other versions)

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse Transcribing RNA Viruses
    • C12N2740/00011—Reverse Transcribing RNA Viruses
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse Transcribing RNA Viruses
    • C12N2740/00011—Reverse Transcribing RNA Viruses
    • C12N2740/10011—Retroviridae
    • C12N2740/14011—Deltaretrovirus, e.g. bovine leukeamia virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/569—Immunoassay; Biospecific binding assay for micro-organisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G01N33/56988—AIDS or HTLV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses, e.g. hepatitis E virus
    • C07K16/1036—Retroviridae, e.g. leukemia viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
    • G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay
    • G01N33/531—Production of immunochemical test materials

Similar Documents

Publication Publication Date Title
Anderson et al. Serological confirmation of human T-lymphotropic virus type I infection in healthy blood and plasma donors
KIYOKAWA et al. Identification of a protein (p40x) encoded by a unique sequence pX of human T-cell leukemia virus type I
US6406841B1 (en) Methods for the detection of HTLV-II antibodies employing novel HTLV-II NRA envelope peptides
Lillehoj et al. Development and evaluation of a human T-cell leukemia virus type I serologic confirmatory assay incorporating a recombinant envelope polypeptide
JP4278174B2 (en) Nucleotide sequence of HIV-1 O group (or subgroup) retroviral antigen
Loughran, JR et al. Epitope mapping of HTLV envelope seroreactivity in LGL leukaemia
DE3752170T2 (en) Synthetic antigen for the detection of AIDS-related diseases
Lal et al. Failure to detect evidence of human T-lymphotropic virus (HTLV) type I and type II in blood donors with isolated gag antibodies to HTLV-I/II
WO1995001457A9 (en) Htlv-iinra compositions and assays for detecting htlv infection
Kohtz et al. Immunological and structural homology between human T-cell leukemia virus type I envelope glycoprotein and a region of human interleukin-2 implicated in binding the beta receptor
AU640921B2 (en) Discrimination between antibodies against HTLV-I, HTLV-II or related retroviruses, new peptides, detection of antibodies and immunoassay kits
US6531574B1 (en) T-lymphotrophic virus
Olsen et al. Serological and virological evidence of human T-lymphotropic virus in systemic lupus erythematosus
Payne et al. Localization of conserved and variable antigenic domains of equine infectious anemia virus envelope glycoproteins using recombinant env-encoded protein fragments produced in Escherichia coli
Sawada et al. High risk of mother‐to‐child transmission of HTLV‐I in p40tax antibody‐positive mothers
EP0439077B1 (en) Synthetic peptide compositions with immunoreactivities to antibodies to HTLV
AU569183B2 (en) Production of human t-cell leukemia (lymphotropic) retrovirus(htlv-i) envelope protein fragments in bacteria and use in seroepidemiological survey of human lymphoid malignancies
HUT61323A (en) And treating htlv-1 peptides and antibodies against them for diagnosting htlv-1 infection and for vaccination against it
US5420244A (en) Methods and compositions for diagnosing HTLV-I associated myelopathy and adult T-cell leukemia
Lal et al. Differential antibody responsiveness to p19 gag results in serological discrimination between human T lymphotropic virus type I and type II
Ehrlich et al. Human T‐lymphotropic virus type I‐associated benign transient immature T‐cell lymphocytosis
JPH04502773A (en) Diagnostic proteins for testing for more than one antibody
LILLEHOJ et al. Virion-associated trans-regulatory protein of human T-cell leukemia virus type I
Sohn et al. Overexpression and purification of human immunodeficiency virus type 1 env derived epitopes in Escherichia coli
Schätzl et al. Prevalence of human T‐Cell lymphotropie virus infections in Germany